Feasibility of Yiqi Fumai lyophilized injection in treatment of novel coronary pneumonia (COVID-19) patients combined with cardiovascular disease

As the rapid outbreak of epidemic novel coronavirus pneumonia (COVID-19) in China, National Health Commission of People's Republic of china and National Administration of Traditional Chinese Medicine have launched different programs of diagnosis and treatment Currently, combining the clinical characteristics of critically patients, the syndrome differentiation of traditional Chinese medicine maintain that Qi-Yin deficiency is one of the main syndrome types, and Shengmai Powder is the main alternative Chinese traditional medicine Yiqi Fumai lyophilized Injection (YQFM) is a modern preparation derived from Shengmai Powder In the present study, we explored the potential pathological process of COVID-19 Meanwhile, the pharmacological effects as well as the possibility of clinical application of YQFM for the treatment of COVID-19 patients with cardiovascular diseases were also evaluated This review will provide evidences for clinicians and patients in the treatment of COVID-19 using Chinese traditional treatment